Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis

McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1111/j.1365-2753.2009.01189.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antipsychotic Agents /adverse effects /economics /metabolism /pharmacology; Canada; Cost-Benefit Analysis; Female; Humans; Long-Term Care; Male; Markov Chains; Quality of Life; Schizophrenia /drug therapy

AccessionNumber
22010001339

Date bibliographic record published
22/12/2010